IBD Patient Care Pathway based on faecal calprotectin

In this video, Dr James Turvill from the York Teaching Hospital introduces and details the York Faecal Calprotectin Care Pathway. He gives a short introduction on the role of calprotectin in stool samples in inflammatory bowel disease (IBD) and its use according to the NICE guidelines. Under his leadership, the local IBD Team developed a Care Pathway to give guidance to primary care physicians on how to use calprotectin in their referral strategy of patients presenting with unspecific gastroenterological symptoms. The pathway is based on cut-off values at 100 µg/g and 250 µg/g. The group with fCAL values below 100 µg/g are treated for irritable bowel syndrome (IBS), in the patients between the two cut-off values, the test is repeated and the patients in the group with values above 250 µg/g are referred to Gastroenterology center to confirm the diagnosis of IBD. The Care Pathway was validated and the results were published earlier this year. Click here to read the Article.


By loading the video, you agree to YouTube's privacy policy.
Learn more

Load video